Comparative Pharmacology
Head-to-head clinical analysis: ALBENDAZOLE versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENDAZOLE versus VANSIL.
ALBENDAZOLE vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Clinical Note
moderateAlbendazole + Digoxin
"Albendazole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlbendazole + Digitoxin
"Albendazole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlbendazole + Deslanoside
"Albendazole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAlbendazole + Acetyldigitoxin
"Albendazole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category D/X
Category C
Anthelmintic
Anthelmintic